论文部分内容阅读
目的观察应用干扰素α-2b(IFNα-2b)联合低剂量HA方案治疗慢性髓细胞白血病(CML)的血液学缓解率和细胞遗传学反应率,寻找治疗CML的新方法。方法采用IFNα-2b(300万U/d)联合HHT(2mg/d,每月用10天)和Ara-C〔(10mg/(m2·d),每月用10天)〕治疗CML慢性期患者27例,治疗后血液学缓解率和细胞遗传学反应率与对照组(IFNα-2b加用羟基脲治疗CML慢性期)作比较。结果IFNα-2b联合低剂量HA方案治疗组治疗6个月的CHR率、总CHR率和细胞遗传学反应率均显著高于对照组(P<0.005、P<0.05、P<0.05),CML急变发生率低于对照组,而且发生急变的时间晚。结论CML慢性期患者采用IFNα-2b联合低剂量HA方案治疗可显著提高CML患者的CHR率,提高CML患者的细胞遗传学反应率,延长CML患者的生存期。
Objective To observe the hematological response rate and cytogenetic response rate of chronic myeloid leukemia (CML) treated with interferon α-2b (IFNα-2b) combined with low-dose HA in order to find a new method for the treatment of CML. Methods Chronic phase of CML was treated with IFNα-2b (3 million U / d) in combination with HHT (2 mg / d for 10 days each month) and Ara-C [10 mg / (m 2 · d) Twenty-seven patients had hematological remission and cytogenetic response after treatment compared with control group (IFNα-2b plus hydroxyurea for CML chronic phase). Results The CHR rate, total CHR rate and cytogenetic response rate of IFNα-2b combined with low-dose HA regimen for 6 months in treatment group were significantly higher than those in control group (P <0.005, P <0.05, P <0.05) The incidence was lower than that of the control group, and the time of emergency was late. Conclusion The treatment of chronic phase CML with IFNα-2b combined with low-dose HA can significantly improve the CHR rate of CML patients, increase the cytogenetic response rate of CML patients and prolong the survival of patients with CML.